Key Highlights

  • Oxford Nanopore Technologies Plc (LSE:ONT) rose 7.22% on 30 September 2026, touching a new 52-week high above 218p.
  • A major German bank raised its price target to 210p on 22 September, and the stock has now traded above that level.
  • A preliminary injunction against a rival sequencing company from Europe's Unified Patent Court strengthened its competitive position.
  • First-half gross Margin rose to 62.2% and the adjusted EBITDA loss more than halved to £22.1 million.
  • The shares have more than doubled from their July low of around 95.7p.

Oxford Nanopore Technologies Plc (LSE:ONT) extended its powerful rally on Wednesday, 30 September 2026, with the shares rising 7.22% to trade around 214p and touching a fresh 52-week high above 218p. The gene sequencing specialist has become one of the best-performing stocks in the FTSE 250 in recent months, driven by a new strategy, improving margins and broker upgrades.

Why Oxford Nanopore Is in Focus

Oxford Nanopore develops sequencing technology that reads DNA and RNA by passing molecules through tiny pores and measuring changes in electrical current. Its devices range from pocket-sized sequencers to high-throughput systems, used in research, clinical diagnostics, biopharma and applied industries.

The stock endured a tough period in early 2026, falling sharply in March when the company trimmed medium-term guidance. It hit a low of around 95.7p in July. Since then, it has more than doubled, as the market embraced the new strategy set out by chief executive Francis Van Parys.

A New Strategy Under New Leadership

Francis Van Parys took over as chief executive in early 2026, replacing co-founder Gordon Sanghera. In August, alongside half-year results, he set out an ambition for more than $700 million in Revenue by 2030 and a longer-term sales target of $1 billion. The plan focuses on the most lucrative opportunities in sequencing, including quality control for mRNA vaccines and clinical applications, while simplifying the product portfolio.

The strategy has been welcomed by the market. One broker upgraded the stock to buy from hold, describing the refocus as addressing key investor concerns.

Improving Financial Performance

For the first half of 2026, revenue rose 12.3% at constant currency to £116.7 million. Although sales came in below management's expectations because of weakness in China and the Middle East, margins improved sharply. Gross margin rose 400 basis points to 62.2%, and the adjusted EBITDA loss more than halved to £22.1 million from £48.3 million. Adjusted operating costs fell 6.9%. The company continues to target adjusted EBITDA breakeven in 2027 and cash breakeven in 2028.

Key Reasons Behind the 7.22% Gain

The first reason is analyst momentum. On 22 September 2026, a major German Investment bank raised its price target to 210p from 195p with a buy rating. The stock has now moved above that target, suggesting investors are pricing in further upside. Consensus ratings are mostly buy.

The second reason is intellectual property protection. On 16 September 2026, Europe's Unified Patent Court granted a preliminary injunction against MGI Tech GmbH, part of a Chinese sequencing group, reinforcing Oxford Nanopore's competitive moat.

The third reason is insider buying. Directors have bought nearly 16,000 shares in recent months, signalling confidence.

The fourth reason is positive momentum. The shares are trading well above their 50-day and 200-day moving averages, attracting momentum-driven investors.

Risks to Consider

Risks include slower revenue growth than originally expected, competition from larger sequencing companies, weakness in China and the Middle East, and continued losses until breakeven. After such a strong rally, the shares may also be vulnerable to profit-taking.

What Investors Are Watching Next

Investors will look for evidence of revenue acceleration in the second half, progress in clinical and biopharma markets, further margin improvement and updates at investor conferences. Full-year trading updates early in 2027 will be key.

Conclusion

Oxford Nanopore Technologies Plc (LSE:ONT) jumped 7.22% today to a new 52-week high as broker upgrades, a patent win and a credible turnaround strategy fuelled buying. The company still needs to deliver on revenue growth, but improving margins and a clear path to profitability have transformed sentiment.